Study: Higher-Dose Dialysate Calcium Better for SHPT
For patients on peritoneal dialysis, 1.75 vs 1.25 mmol/L dialysate calcium was superior at reducing intact parathyroid hormone levels, meta-analysis revealed.
Secondary Hyperparathyroidism
Calcitriol Loading May Not Prevent Post-PTx Hungry Bone Syndrome
In a small study, hungry bone syndrome developed in nearly 29% of patients despite receiving high-dose calcitriol prior to total parathyroidectomy with autotransplantation.
Holistic Approach to Managing SHPT Recommended for Older Adults
A new review suggests transitioning from a disease-oriented approach to a patient-oriented approach for better risk-benefit balance.
Post-Parathyroidectomy Hungry Bone Syndrome Risk Factors ID’d
Hungry bone syndrome developed in nearly 88% of patients following parathyroidectomy with autotransplantation for refractory secondary hyperthyroidism.
Parathyroid Hormone Predicts Fracture, Vascular Events, Death in CKD
In a study of CKD patients, patients with baseline PTH levels of 0, 69, and 58 pg/mL had the lowest risks for fracture, vascular events, and death, respectively.
Preoperative Potassium Predicts Hyperkalemia Post-Parathyroidectomy
In a study of hemodialysis patients, pre-operative potassium higher than 3.9 mmol/L correlated with greater risk for hyperkalemia after parathyroidectomy.
Vertebral Fracture Common in ESRD
In a small study, 34% of dialysis patients had vertebral fractures, and patients in the highest tertile of parathyroid hormone level had a nearly 3-fold increased risk of these fractures compared with those in the middle tertile.
Higher Vitamin D Target May Be Needed to Manage SHPT
New data support aggressive vitamin D repletion to a revised serum 25-hydroxyvitamin D target of at least 51 ng/mL in patients with chronic kidney disease.
Pre-Transplant Cinacalcet May Increase the Risk of Persistent SHPT
Twice as many patients taking a high cinacalcet dose before transplantation required subsequent parathyroidectomy persistent secondary hyperparathyroidism.
Cinacalcet Frequently Discontinued, Reinitiated
A European study of hemodialysis patients who were new users of cinacalcet found that the drug was discontinued in 35% of patients after 1 year.
Next post in Secondary Hyperparathyroidism
